Naltrexone–bupropion for managing overweight and obesity

  • Technology appraisal guidance
  • TA494
  • Published: 

History

Documents created during the development process.

Expected publication

Appeal

Final appraisal determination

Draft guidance

Invitation to participate

Draft scope documents

Draft scope documents

Obesity, overweight with risk factors - naltrexone-bupropion (prolonged release): draft scope for consultation (pre-referral) - March 2014

Obesity, overweight with risk factors - naltrexone-bupropion (prolonged release): provisional matrix (pre-referral) - March 2014